Duloxetine

also known as Cymbalta · Duloxetine Hydrochloride · Duloxetine HCl · Ariclaim · Cymbalta (duloxetine) · Cymbatex · DLX · Drizalma sprinkle · +18 more

Small molecule targets CYP2D6, SLC6A2, SLC6A4 via inhibition

Developed for: major depressive disorder · depressive disorder · female stress incontinence · fibromyalgia · chronic pain syndrome · osteoarthritis, knee · diabetic polyneuropathy · generalized anxiety disorder
+49 more
· neuropathy, painful · diabetic neuropathy · anxiety disorder · chemotherapy-induced neuropathy · dysthymic disorder · osteoarthritis · breast cancer · irritable bowel syndrome · musculoskeletal system disorder · Parkinson disease · peripheral neuropathy · post-traumatic stress disorder · anxiety · diabetes mellitus · multiple sclerosis · obsessive-compulsive disorder · schizophrenia · substance-related disorder · alcohol dependence · alcohol-related disorders · atypical depressive disorder · binge eating disorder · chemotherapy-induced toxicity · cognitive impairment with or without cerebellar ataxia · delirium · headache disorder · idiopathic progressive polyneuropathy · inflammatory bowel disease · interstitial lung disease · migraine disorder · myalgic encephalomeyelitis/chronic fatigue syndrome · myofascial pain syndrome · panic disorder · postherpetic neuralgia · postpartum depression · psychotic disorder · systemic lupus erythematosus · temporomandibular joint disorder · urinary bladder disorder · urinary system disorder · attention deficit-hyperactivity disorder · biliary dyskinesia · burning mouth syndrome · cirrhosis of liver · intervertebral disk degenerative disorder · methamphetamine dependence · mixed anxiety and depressive disorder · osteoarthritis, hand · persian gulf syndrome
Investigated by: Eli Lilly and Company · Boehringer Ingelheim · Shionogi · New York State Psychiatric Institute · Assiut University · Indiana University
+168 more
· Massachusetts General Hospital · National Cancer Institute (NCI) · National Institute of Mental Health (NIMH) · Stanford University · H. Lundbeck A/S · Mayo Clinic · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Pfizer · The Catholic University of Korea · University of Michigan · Wake Forest University Health Sciences · Alliance for Clinical Trials in Oncology · Beijing Tiantan Hospital · Cairo University · Dr. Reddy's Laboratories Limited · Duke University · Far Eastern Memorial Hospital · GlaxoSmithKline · Hospital for Special Surgery, New York · Laboratorios Andromaco S.A. · Medical University of Vienna · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · National Institutes of Health (NIH) · National Taiwan University Hospital · Northwestern University · Patient-Centered Outcomes Research Institute · Rambam Health Care Campus · Sunnybrook Health Sciences Centre · University of Cincinnati · University of Maryland, Baltimore · University of Michigan Rogel Cancer Center · University of Pennsylvania · Yale University · 3ARH · Aalborg University Hospital · Aarhus University Hospital · Aga Khan University · Ajay Wasan, MD, Msc · Albany Medical College · Alto Neuroscience · American Cancer Society, Inc. · Amira Hassan Ahmed Ali · Arthritis Research UK · AstraZeneca · Baoding First Central Hospital · Baylor College of Medicine · Beijing Tsinghua Chang Gung Hospital · Beth Israel Deaconess Medical Center · Boston Medical Center · Brown, Theodore R., M.D., MPH · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Cangzhou Central Hospital · Canive, Jose M., M.D. · Carlos III Health Institute · Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak · Central Denmark Region · Central Hospital, Nancy, France · Central Institute of Mental Health, Mannheim · Central Visitation, Region Hovedstaden · Centre Hospitalier Universitaire Vaudois · Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal · Children's Hospital of Chongqing Medical University · China-Japan Friendship Hospital · Craig Rush · Dr. Jesus Gutierrez Stone · Dr. Nazanin Alavi · Emory University · Erzincan Military Hospital · European Organisation for Research and Treatment of Cancer - EORTC · Fight AIDS and Infectious Diseases Foundation · First Affiliated Hospital of Chongqing Medical University · First Hospital of China Medical University · Forest Laboratories · French Parkinson Association · all 174 on the full record

Regulatory milestones approvals, filings & regulatory actions · 13 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed chronic pain syndrome 1 milestone
Filed	US (FDA)	Cymbalta	chronic pain syndrome	2009-06-03	“has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA).” lilly.com ↗
Filed depressive disorder 1 milestone
Filed	US (FDA)	—	depressive disorder	2002-01-24	“Lilly submitted an NDA to the FDA for duloxetine” lilly.com ↗
Filed fibromyalgia 1 milestone
Filed	US (FDA)	Cymbalta	fibromyalgia	2007-08-21	“recently submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta for the management of fibromyalgia.” lilly.com ↗ “The company submitted a supplemental new drug application to the U.S. Food and Drug Administration for Cymbalta for the management of fibromyalgia.” lilly.com ↗
Filed generalized anxiety disorder 1 milestone
Filed	US (FDA)	Cymbalta	generalized anxiety disorder	2006-05-09	“submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the treatment of generalized...” lilly.com ↗
Approved Indication not stated 4 milestones
Label expansion	US (FDA)	DRIZALMA SPRINKLE	—	2021-07-23	fda.gov ↗
Label expansions (6)	US (FDA)	CYMBALTA	—	2007-02-23 – 2020-04-20	fda.gov ↗
Approved	EU (EMA)	Yentreve	—	2004-08-11	europa.eu ↗
Approved	US (FDA)	CYMBALTA	—	2004-08-03	fda.gov ↗

Trials 251 · started per year

today

US approved 2004

EU approved 2004

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT05292066	Oct → Dec 2022	neuropathy, painful	Aga Khan University	Unknown	No outcome recorded
Phase 0	NCT03623711	Aug 2018 → Dec 2022	major depressive disorder	Yuqi Cheng	Unknown	No outcome recorded
Phase 0	NCT00763178	Feb 2007 → Apr 2009	post-traumatic stress disorder	Yale University	Completed	No outcome recorded
Phase 115 trials
Phase 1	NCT04836533	Jan 2023	depressive disorder	Queens College, The City University of New York	Withdrawn	No outcome recorded
Phase 1	NCT05065671	Feb 2022 → Sep 2025	—	Rutgers, The State University of New Jersey	Completed	No outcome recorded
Phase 1	NCT04751318	Feb 2021	—	Laboratorios Andromaco S.A.	Completed	No outcome recorded
Phase 1	NCT04723238	Jan → Feb 2021	—	Laboratorios Andromaco S.A.	Completed	No outcome recorded
Phase 1	NCT03575403	Sep 2018 → Mar 2023	alcohol-related disorders	Craig Rush	Completed	No outcome recorded
Phase 1	NCT02869035	Aug 2016 → Jul 2019	major depressive disorder	Rigshospitalet, Denmark	Completed	No outcome recorded
Phase 1	NCT02700711	Feb 2016 → Jun 2018	substance-related disorder	University of Kentucky	Completed	No outcome recorded
Phase 1	NCT02174822	Jan → Mar 2014	—	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 1	NCT00990067	Nov 2009 → May 2010	mood disorder, substance-related disorder	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 1	NCT00933452	Jul → Nov 2009	—	Shanghai Mental Health Center	Completed	No outcome recorded
Phase 1	NCT02291367	May 2008	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 1	NCT02291341	May 2008	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 1	NCT00414323	Nov 2006 → May 2007	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT00387413	Oct 2006 → May 2007	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02232542	Jun → Aug 2003	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT05949229	Aug 2023 → Aug 2026 overdue	delirium	Amira Hassan Ahmed Ali	Not yet recruiting	No outcome recorded
Phase 1/2	NCT05814640	Feb 2023 → Dec 2026 expected	major depressive disorder, splenic sequestration	First Affiliated Hospital of Chongqing Medical University	Recruiting	No outcome recorded
Phase 224 trials · 3 missed
Phase 2	NCT07431606	May 2026 → Mar 2027 expected	inflammatory bowel disease	University of Pennsylvania	Recruiting	No outcome recorded
Phase 2	NCT06614322	Feb 2026 → Jun 2028 expected	chemotherapy-induced neuropathy, diabetic polyneuropathy, neuropathy, painful	University of Rochester	Recruiting	No outcome recorded
Phase 2	NCT06551051	Aug 2024 → Dec 2025 overdue	cancer	Fudan University	Recruiting	No outcome recorded
Phase 2	NCT05611749	May 2023 → Mar 2024	chronic pain syndrome, opiate dependence	Scripps Health	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT05120934	Nov 2021 → Oct 2026 expected	interstitial lung disease	Mayo Clinic	Recruiting	No outcome recorded
Phase 2	NCT05110144	Nov 2021 → Dec 2026 expected	—	Mayo Clinic	Recruiting	No outcome recorded
Phase 2	NCT04111627	Oct 2021 → Aug 2025	depressive disorder, osteoarthritis, knee	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT04970121	Aug 2021 → Jul 2027 expected	cancer, chemotherapy-induced neuropathy	Yan Yang, MD, Ph.D	Recruiting	No outcome recorded
Phase 2	NCT04437485	Oct 2020 → Aug 2022	dysthymic disorder, major depressive disorder, prediabetes syndrome, type 2 diabetes mellitus	Indiana University	Completed	Missed primary
Phase 2	NCT04560673	Jul 2020 → Dec 2026 expected	cancer, chemotherapy-induced neuropathy, hematopoietic and lymphoid cell neoplasm	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT03315533	Jan 2018 → Mar 2019	musculoskeletal system disorder	Rhode Island Hospital	Completed	No outcome recorded
Phase 2	NCT03038867	Dec 2016 → Aug 2018	depressive disorder, male infertility	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 2	NCT02857244	Nov 2016 → Nov 2017	Parkinson disease	University of Chicago	Withdrawn	No outcome recorded
Phase 2	NCT02458690	Jul 2015 → Aug 2019	coronary artery disorder, dysthymic disorder, major depressive disorder, stroke disorder	Indiana University	Completed	Missed primary
Phase 2	NCT02307305	Aug 2014 → Dec 2016	neuropathy, painful	Hanyang University Seoul Hospital	Unknown	No outcome recorded
Phase 2	NCT01912612	Oct 2013 → Jun 2019	—	University of Michigan Rogel Cancer Center	Completed	No outcome recorded
Phase 2	NCT00929344	Jul 2009 → Oct 2014	alcohol dependence	The Scripps Research Institute	Completed	No outcome recorded
Phase 2	NCT00863057	May 2009 → Dec 2010	HIV infectious disease, peripheral neuropathy	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	Missed primary Stop: Enrollment
Phase 2	NCT00837941	Apr → Aug 2009	diabetic polyneuropathy	Merck Sharp & Dohme LLC	Withdrawn	No outcome recorded
Phase 2	NCT00742573	Aug 2008 → Jan 2014	major depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00529789	Aug 2007 → Sep 2008	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00475696	Nov 2002 → Mar 2005	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00190606	Jan 2002 → Apr 2006	urinary system disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00190567	Oct 2001 → Apr 2006	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded

Phase 2/37 trials · 1 met primary · 1 missed
Phase 2/3	NCT04747314	Mar 2021 → Nov 2024	anxiety, chronic pain syndrome	Ajay Wasan, MD, Msc	Completed	No outcome recorded
Phase 2/3	NCT04137107	Jun 2020 → Feb 2026 overdue	digestive system carcinoma	Alliance for Clinical Trials in Oncology	Active not recruiting	No outcome recorded
Phase 2/3	NCT00370656	Feb 2007 → May 2009	diabetes mellitus, peripheral neuropathy	University of Surrey	Completed	No outcome recorded
Phase 2/3	NCT00457730	Jan 2007 → Aug 2012	multiple sclerosis	Brown, Theodore R., M.D., MPH	Completed	Met primary
Phase 2/3	NCT00375973	Sep 2006 → Jun 2012	myalgic encephalomeyelitis/chronic fatigue syndrome	University of Cincinnati	Completed	Missed primary
Phase 2/3	NCT00215228	Jul 2005 → Aug 2007	major depressive disorder	Duke University	Completed	No outcome recorded
Phase 2/3	NCT00136383	Mar 2005 → Jun 2007	depressive disorder	Duke University	Completed	No outcome recorded
Phase 380 trials · 27 met primary · 9 missed
Phase 3	NCT06407401	Dec 2024 → Apr 2028 expected	Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, musculoskeletal system disorder	European Organisation for Research and Treatment of Cancer - EORTC	Not yet recruiting	No outcome recorded
Phase 3	NCT06606067	Sep 2024 → Jul 2026 overdue	chronic pain syndrome	Parc de Salut Mar	Active not recruiting	No outcome recorded
Phase 3	NCT05677295	Apr 2023 → Dec 2024	female stress incontinence	Far Eastern Memorial Hospital	Unknown	No outcome recorded
Phase 3	NCT03068247	Nov 2021 → May 2023	major depressive disorder	University of Utah	Withdrawn	No outcome recorded
Phase 3	NCT04364997	Jun 2020 → Sep 2021	major depressive disorder	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT04412876	May 2020	female stress incontinence	Far Eastern Memorial Hospital	Withdrawn	No outcome recorded
Phase 3	NCT03395353	Jan 2018 → Jul 2020	depressive disorder	Shionogi	Terminated	No outcome recorded Stop: Business
Phase 3	NCT03315793	Dec 2017 → Nov 2019	depressive disorder	Shionogi	Completed	Missed primary
Phase 3	NCT03249168	Oct 2017 → Nov 2018	—	Assiut University	Completed	No outcome recorded
Phase 3	NCT02374567	Jan 2015 → Jun 2017	anxiety disorder, dementia, depressive disorder, schizophrenia +1	Hannover Medical School	Terminated	No outcome recorded
Phase 3	NCT02335346	Jan 2015 → Mar 2016	osteoarthritis, knee	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT02248480	Oct 2014 → Jun 2015	osteoarthritis, knee	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT01914666	Sep 2013 → Dec 2014	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT01931475	Sep 2013 → Mar 2015	osteoarthritis	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT01598298	May 2013 → Dec 2016	breast cancer, musculoskeletal system disorder	SWOG Cancer Research Network	Completed	Met primary
Phase 3	NCT01855919	May 2013 → Jul 2014	—	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT01621191	Jun 2012 → Feb 2014	fibromyalgia	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT01552057	Mar 2012 → Dec 2013	fibromyalgia	Eli Lilly and Company	Completed	Mixed
Phase 3	NCT01226511	Jun 2011 → Feb 2013	anxiety disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT01504178	May 2011 → Dec 2015	Parkinson disease	University Hospital, Toulouse	Completed	No outcome recorded
Phase 3	NCT01179672	Apr 2011 → Aug 2013	diabetic polyneuropathy	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT01237587	Mar 2011 → May 2017	fibromyalgia	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT01140906	May 2010 → Sep 2011	major depressive disorder	H. Lundbeck A/S	Completed	Met primary
Phase 3	NCT01089556	Mar 2010 → Nov 2011	diabetic neuropathy	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT01018680	Nov 2009 → Apr 2011	osteoarthritis, knee	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00989157	Sep 2009 → Oct 2012	—	Neuropsychiatric Research Institute, Fargo, North Dakota	Completed	No outcome recorded
Phase 3	NCT00945945	Jul 2009 → May 2010	osteoarthritis, knee	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT00849901	Mar 2009 → Mar 2011	major depressive disorder	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT00849693	Mar 2009 → Feb 2011	major depressive disorder	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT00811252	Jan 2009 → Feb 2010	major depressive disorder	H. Lundbeck A/S	Completed	Met primary
Phase 3	NCT00803361	Dec 2008 → Jan 2010	generalized anxiety disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00755807	Oct 2008 → Aug 2010	multiple sclerosis	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00767806	Sep 2008 → Jul 2009	chronic pain syndrome	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00489411	Apr 2008 → Jan 2012	cancer of unknown primary site, chemotherapy-induced toxicity, peripheral neuropathy	Alliance for Clinical Trials in Oncology	Completed	Met primary
Phase 3	NCT00641719	Mar 2008 → Mar 2010	diabetic neuropathy	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00635219	Feb 2008 → Apr 2009	major depressive disorder	H. Lundbeck A/S	Completed	Missed primary
Phase 3	NCT00552175	Nov 2007 → Mar 2009	diabetic neuropathy	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00433290	Feb 2007 → May 2008	osteoarthritis, knee	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00552682	Jan 2007 → Jul 2009	HIV infectious disease, fibromyalgia	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 3	NCT00424593	Jan → Dec 2007	—	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00408876	Dec 2006 → Nov 2007	—	Eli Lilly and Company	Completed	Mixed
Phase 3	NCT00408993	Dec 2006 → Feb 2008	diabetic neuropathy	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT00408421	Nov 2006 → Oct 2007	osteoarthritis, knee	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00384033	Sep 2006 → Sep 2007	major depressive disorder	Pfizer	Completed	Missed primary
Phase 3	NCT00366652	Sep 2006	major depressive disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00321490	Apr 2006 → May 2007	major depressive disorder	AstraZeneca	Completed	Met primary
Phase 3	NCT00583193	Dec 2005 → Jun 2008	post-traumatic stress disorder	Canive, Jose M., M.D.	Unknown	No outcome recorded
Phase 3	NCT00233025	Sep 2005 → Jun 2007	fibromyalgia	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00125892	Jul 2005 → Mar 2007	fibromyalgia	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00190866	Jun 2005 → Jun 2007	fibromyalgia	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT02232555	May 2005 → May 2006	major depressive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00191919	May 2005 → May 2006	major depressive disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00122837	Apr 2005 → Jan 2007	anxiety disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00105989	Mar 2005 → Jan 2008	major depressive disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00191594	Mar 2005 → Aug 2006	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00122863	Jan 2005 → Mar 2007	anxiety disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00190853	Jan 2005 → Sep 2006	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00122850	Oct 2004 → Nov 2005	anxiety disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00475969	Aug 2004 → Jun 2005	generalized anxiety disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00122824	Jun 2004 → Sep 2005	generalized anxiety disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00191685	May 2004 → Sep 2005	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00489775	Jan 2004 → Jun 2005	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00475397	Dec 2003 → Oct 2004	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00073411	Nov 2003 → May 2005	depressive disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00190827	Sep 2003 → May 2006	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00190814	Sep 2003 → May 2006	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00475358	Apr 2003 → Feb 2005	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00062673	Mar 2003 → Jul 2004	depressive disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00190996	Jan 2003 → Jun 2006	female stress incontinence	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00042562	Dec 2002 → Dec 2003	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00489073	Nov 2002 → Dec 2003	fibromyalgia	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00058968	Oct 2002 → Mar 2005	diabetic polyneuropathy	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00042575	Jun → Aug 2002	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00036309	May 2002 → Jul 2003	depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00036335	Mar 2002 → Jan 2003	depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191204	Sep 2001 → May 2006	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00190619	May 2001 → May 2006	urinary bladder disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191087	Apr 2001 → May 2006	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00190632	Mar 2001 → Apr 2006	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00190645	Feb 2001 → May 2006	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded

Phase 487 trials · 12 met primary · 8 missed
Phase 4	NCT07795593	Oct 2026 → May 2031 expected	diabetic kidney disease, diabetic neuropathy	University of Michigan	Not yet recruiting	No outcome recorded
Phase 4	NCT05976347	Jun 2025 → May 2027 expected	depressive disorder	Wake Forest University Health Sciences	Recruiting	No outcome recorded
Phase 4	NCT06807866	Mar 2025 → Dec 2026 expected	—	University of Miami	Recruiting	No outcome recorded
Phase 4	NCT06423716	Nov 2024 → Jul 2026 overdue	osteoarthritis, knee	Sunnybrook Health Sciences Centre	Recruiting	No outcome recorded
Phase 4	NCT05851898	Apr 2024 → Dec 2028 expected	osteoporosis	Wake Forest University Health Sciences	Recruiting	No outcome recorded
Phase 4	NCT06232473	Jan 2024 → Nov 2027 expected	—	Aarhus University Hospital	Recruiting	No outcome recorded
Phase 4	NCT05851976	Oct 2023 → May 2027 expected	—	Montefiore Medical Center	Recruiting	No outcome recorded
Phase 4	NCT04639011	Oct 2022 → Dec 2023	—	Boston Medical Center	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT05086393	Nov 2021 → Jun 2025	neuropathy, painful	Rush University Medical Center	Completed	No outcome recorded
Phase 4	NCT04870957	Jun 2021 → Oct 2024	chronic pain syndrome	University of Michigan	Completed	No outcome recorded
Phase 4	NCT04782310	Mar → Aug 2021	—	Cairo University	Unknown	No outcome recorded
Phase 4	NCT04697693	Mar → May 2021	major depressive disorder, post-traumatic stress disorder	New York State Psychiatric Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT04395001	Feb 2021 → Jul 2024	chronic pain syndrome	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 4	NCT04388189	Oct 2020 → May 2023	major depressive disorder	Alto Neuroscience	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT03729284	Mar → Jun 2020	—	Pfizer	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT03794154	Mar → Jun 2020	—	Pfizer	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT04246619	Nov 2019 → Dec 2021	diabetic polyneuropathy	KRKA	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT04117893	Oct 2019 → Jun 2021	chronic pain syndrome, osteoarthritis, knee	Beijing Tiantan Hospital	Completed	No outcome recorded
Phase 4	NCT03792828	Jan → Oct 2019	osteoarthritis, knee	Seoul National University Hospital	Unknown	No outcome recorded
Phase 4	NCT03548454	Sep 2018 → Dec 2023	chronic pain syndrome	Stanford University	Completed	No outcome recorded
Phase 4	NCT03271151	Sep 2017 → Dec 2020	arthropathy, chronic pain syndrome	Hospital for Special Surgery, New York	Completed	No outcome recorded
Phase 4	NCT02846701	Nov 2016 → Jun 2017	neuropathy, painful	University Hospital, Strasbourg, France	Completed	No outcome recorded
Phase 4	NCT02351440	Apr 2016 → Aug 2017	—	Northwestern University	Withdrawn	No outcome recorded
Phase 4	NCT02590874	Jan 2016 → Jul 2017	cognitive impairment with or without cerebellar ataxia, depressive disorder	University of North Texas Health Science Center	Completed	No outcome recorded
Phase 4	NCT02711215	May 2015 → Jan 2020	major depressive disorder	Medical University of Vienna	Unknown	No outcome recorded
Phase 4	NCT02417935	Apr 2015 → May 2017	diabetic polyneuropathy	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT02208778	Dec 2014 → Jun 2016	chronic pain syndrome, osteoarthritis	University of Nottingham	Completed	No outcome recorded
Phase 4	NCT02260388	Oct 2014 → Sep 2017	idiopathic progressive polyneuropathy	University of Kansas Medical Center	Completed	No outcome recorded
Phase 4	NCT01973283	Feb 2014 → Dec 2019	dysthymic disorder, major depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 4	NCT02005601	Nov 2013 → May 2015	—	Hospital for Special Surgery, New York	Completed	No outcome recorded
Phase 4	NCT01916824	Aug 2013 → Dec 2015	major depressive disorder	Emory University	Completed	No outcome recorded
Phase 4	NCT01796132	Aug 2012 → Dec 2016	depressive disorder, lactation disease	Centre Hospitalier Universitaire Vaudois	Unknown	No outcome recorded
Phase 4	NCT01619566	Jun 2012 → Jan 2015	fibromyalgia	University of California, San Diego	Withdrawn	No outcome recorded
Phase 4	NCT01558700	Mar 2012 → Apr 2014	osteoarthritis	Northwestern University	Completed	No outcome recorded
Phase 4	NCT01391221	Jul 2011 → Aug 2013	major depressive disorder	Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal	Unknown	No outcome recorded
Phase 4	NCT01118780	Oct 2010 → Jul 2012	generalized anxiety disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT01166048	May 2010 → Jun 2014	chronic pain syndrome	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT01070329	Mar 2010 → Mar 2011	major depressive disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT01089621	Mar → Aug 2010	fibromyalgia	Eli Lilly and Company	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01078870	Feb 2010 → Jan 2011	schizophrenia	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT01051466	Jan 2010 → Mar 2013	major depressive disorder	Eli Lilly and Company	Completed	Missed primary
Phase 4	NCT01000805	Nov 2009 → Oct 2010	major depressive disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00961298	Sep 2009 → Dec 2011	generalized anxiety disorder, irritable bowel syndrome	West Penn Allegheny Health System	Completed	No outcome recorded
Phase 4	NCT00965081	Sep 2009 → Nov 2010	fibromyalgia	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00985504	Sep 2009 → Dec 2010	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00960986	Aug 2009 → Feb 2011	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT01117857	Aug 2009 → Jun 2011	depressive disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00889369	May 2009 → Feb 2012	major depressive disorder	Hamilton Health Sciences Corporation	Unknown	No outcome recorded
Phase 4	NCT00844194	Feb 2009 → Jun 2010	diabetic polyneuropathy, major depressive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT01754493	Dec 2008 → Dec 2014	irritable bowel syndrome, major depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 4	NCT00810069	Nov 2008 → Feb 2010	major depressive disorder	Eli Lilly and Company	Completed	Missed primary
Phase 4	NCT00673452	Jun 2008 → Apr 2009	fibromyalgia	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00696774	Jun 2008 → Jul 2009	major depressive disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00666757	May 2008 → Feb 2009	depressive disorder	Eli Lilly and Company	Completed	Missed primary
Phase 4	NCT00658931	Apr 2008 → Apr 2010	major depressive disorder	Jefferson Clinic, P.C.	Unknown	No outcome recorded
Phase 4	NCT00532480	Sep 2007 → Apr 2009	major depressive disorder	Indiana University	Completed	No outcome recorded
Phase 4	NCT00536471	Sep 2007 → May 2008	major depressive disorder	Eli Lilly and Company	Completed	Mixed
Phase 4	NCT00443352	Aug 2007 → Nov 2012	migraine disorder	Thomas Jefferson University	Completed	No outcome recorded
Phase 4	NCT00696293	May 2007 → Mar 2010	major depressive disorder	University of Pittsburgh	Completed	No outcome recorded
Phase 4	NCT00437125	Mar 2007 → Jul 2009	Parkinson disease, major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT02229825	Feb 2007 → Aug 2008	major depressive disorder	Boehringer Ingelheim	Completed	Missed primary
Phase 4	NCT00422162	Feb 2007 → Aug 2008	major depressive disorder	Eli Lilly and Company	Completed	Missed primary
Phase 4	NCT00517985	Feb 2007 → Jun 2008	major depressive disorder	University of Arizona	Completed	No outcome recorded
Phase 4	NCT00398632	Nov 2006 → Apr 2009	depressive disorder	Stanford University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00401258	Nov 2006 → Feb 2008	irritable bowel syndrome	Mclean Hospital	Completed	Met primary
Phase 4	NCT00406848	Nov 2006 → Jul 2009	major depressive disorder	Eli Lilly and Company	Completed	Missed primary
Phase 4	NCT00607789	Oct 2006 → Oct 2009	binge eating disorder, depressive disorder	University of Cincinnati	Completed	Missed primary
Phase 4	NCT00385671	Sep 2006 → Aug 2009	diabetic polyneuropathy	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00360724	Aug 2006 → Dec 2011	depressive disorder, dysthymic disorder	New York State Psychiatric Institute	Completed	Met primary
Phase 4	NCT00438971	Aug 2006 → Jan 2009	panic disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00531895	Apr 2006 → Mar 2007	headache disorder, major depressive disorder	Kraepelin Psiquiatria Clinica	Completed	No outcome recorded
Phase 4	NCT00322621	Apr 2006 → Oct 2007	diabetic neuropathy	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT01035073	Apr 2006 → May 2009	major depressive disorder, myofascial pain syndrome	University of Pennsylvania	Completed	No outcome recorded
Phase 4	NCT01852383	Jan 2006 → Sep 2010	depressive disorder, dysthymic disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 4	NCT00464698	Dec 2005 → Dec 2013	obsessive-compulsive disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00266643	Dec 2005 → Apr 2007	diabetic polyneuropathy	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00244296	Oct 2005 → Jan 2007	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00224302	Aug 2005 → Nov 2007	psychotic disorder	Central Institute of Mental Health, Mannheim	Completed	No outcome recorded
Phase 4	NCT00296699	Mar 2005 → Jun 2007	atypical depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 4	NCT00191061	Oct 2004 → Jan 2006	major depressive disorder	Eli Lilly and Company	Completed	Missed primary
Phase 4	NCT00118430	Sep 2004 → Jul 2008	depressive disorder	Indiana University	Completed	Met primary
Phase 4	NCT00609557	Sep 2004 → Feb 2007	osteoarthritis	University of Washington	Completed	No outcome recorded
Phase 4	NCT00479726	Aug 2004 → Jan 2005	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00191932	Aug 2004 → Mar 2006	major depressive disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00190905	Feb 2004 → Jul 2005	female stress incontinence	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00071695	Jul 2003 → May 2004	depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00067912	Apr 2003 → Mar 2004	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded

Phase not applicable32 trials · 1 met primary · 1 missed
—	NCT07731750	Jul 2026 → Feb 2030 expected	chronic pain syndrome	University of Michigan	Recruiting	No outcome recorded
—	NCT07654179	Jun 2026 → Jun 2027 expected	depressive disorder, obesity disorder	Riphah International University	Recruiting	No outcome recorded
—	NCT07421427	Feb 2026 → Jan 2027 expected	chronic pain syndrome	Cairo University	Recruiting	No outcome recorded
—	NCT06711978	Dec 2024 → May 2025 overdue	chemotherapy-induced neuropathy	Pusan National University Yangsan Hospital	Not yet recruiting	No outcome recorded
—	NCT06429605	May → Dec 2024	—	Erzincan Military Hospital	Completed	No outcome recorded
—	NCT05311774	Apr 2022 → Oct 2025	—	Assiut University	Completed	No outcome recorded
—	NCT04313335	Mar 2021 → May 2023	postherpetic neuralgia	Beijing Tiantan Hospital	Completed	Missed primary
—	NCT04732455	Jan 2021 → Jun 2022	breast cancer, chemotherapy-induced neuropathy	Gamal Mohamed Taha Abouelmagd	Completed	No outcome recorded
—	NCT04719585	Jan 2021 → Dec 2022	osteoarthritis, knee	The Catholic University of Korea	Unknown	No outcome recorded
—	NCT04478526	Apr 2020 → May 2021	generalized anxiety disorder	Dr. Nazanin Alavi	Completed	No outcome recorded
—	NCT03880916	Mar 2019 → Mar 2020	osteoarthritis, knee	The Catholic University of Korea	Unknown	No outcome recorded
—	NCT03560427	Sep 2018 → Mar 2020	—	Assiut University	Completed	No outcome recorded
—	NCT03549026	Jan 2018 → Dec 2019	—	Assiut University	Unknown	No outcome recorded
—	NCT03276689	Oct 2017 → Dec 2020	neuropathy, painful	Rambam Health Care Campus	Completed	No outcome recorded
—	NCT03148522	Jun 2017 → Dec 2021	—	Peking University	Unknown	No outcome recorded
—	NCT03054220	Jul 2016 → Dec 2018	—	Jules Desmeules	Completed	No outcome recorded
—	NCT02600247	Nov 2015 → Nov 2016	osteoarthritis	The Catholic University of Korea	Unknown	No outcome recorded
—	NCT03121573	Dec 2014 → Sep 2016	major depressive disorder	Taichung Veterans General Hospital	Completed	No outcome recorded
—	NCT01650740	Aug 2012 → Aug 2014	major depressive disorder	Sunnybrook Health Sciences Centre	Terminated	No outcome recorded Stop: Enrollment
—	NCT01269866	Dec 2010 → May 2012	systemic lupus erythematosus	Dr. Jesus Gutierrez Stone	Completed	No outcome recorded
—	NCT01425827	Nov 2010 → Jun 2011	—	University of Alexandria	Completed	Met primary
—	NCT01363284	Jun 2010 → Aug 2012	diabetes mellitus, neuropathy, painful	Rambam Health Care Campus	Completed	No outcome recorded
—	NCT01127490	May 2010 → Sep 2015	fibromyalgia	Albany Medical College	Completed	No outcome recorded
—	NCT00981149	May 2009 → Nov 2011	temporomandibular joint disorder	University of Maryland, Baltimore	Completed	No outcome recorded
—	NCT01028352	Oct 2008 → Nov 2010	breast cancer	University of Michigan Rogel Cancer Center	Completed	No outcome recorded
—	NCT00617045	Jul 2007 → Dec 2012	major depressive disorder, postpartum depression	Yale University	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00491348	Apr 2007 → Nov 2008	anxiety	National Taiwan University Hospital	Terminated	No outcome recorded
—	NCT00425230	Jan → Jun 2007	—	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
—	NCT00388414	Sep 2006 → Jan 2010	—	Stanford University	Completed	No outcome recorded
—	NCT00933439	Feb 2005 → Sep 2007	major depressive disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
—	NCT00185575	Sep 2004 → Apr 2006	depressive disorder	Stanford University	Completed	No outcome recorded
—	NCT00399022	—	obsessive-compulsive disorder	Sheba Medical Center	Withdrawn	No outcome recorded Stop: Business

Phase not stated1 trial
—	NCT00071708	—	diabetic polyneuropathy, fibromyalgia, generalized anxiety disorder, major depressive disorder	Eli Lilly and Company	Approved for marketing	No outcome recorded
Comparator or background therapy138 trials
Phase 0	NCT07400471 Comparator	Feb 2026 → Mar 2027 expected	—	Chattogram International Dental College	Recruiting	No outcome recorded
Phase 0	NCT05508516 Comparator	Sep 2022 → Oct 2024	fibromyalgia	China-Japan Friendship Hospital	Completed	No outcome recorded
Phase 0	NCT01688570 Comparator	Aug 2011 → May 2015	stroke disorder	Medical College of Wisconsin	Completed	No outcome recorded
Phase 1	NCT06965569 Background	Apr → Dec 2025	—	Alar Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 1	NCT04862845 Comparator	Jul 2021 → Dec 2025	—	Cairo University	Completed	No outcome recorded
Show all 138 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 51

Date	Issuer	Release
2021-02-15	Upsher-Smith Laboratories	Regulatory Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths upsher-smith.com ↗ Osaka, Japan – February 15, 2021 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for eight generic drugs with 20 strengths.
2020-07-27	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Regulatory VOLUNTARY ANNOUNCEMENT - "DULOXETINE HYDROCHLORIDE ENTERIC CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗ The board of directors (the “ Board”) of CSPC Pharmaceutical Group Limited (the “ Company ”, together with its subsidiaries, the “Group”) is pleased to announce that the “Duloxetine Hydrochloride Enteric Capsules (20mg, 30mg, 60mg)” (the “ Product ”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.*ʮ̡, a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, being the second generic drug of this type passing the consistency of quality and efficacy evaluation in China.
2013-12-12	Sun Pharmaceutical Industries, Inc.	Regulatory Sun Pharma announces US FDA approval for generic Cymbalta® sunpharma.com ↗ Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that the US FDA has granted its subsidiary final approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta ®, Duloxetine Delayed-Release Capsules USP, 20 mg, 30 mg and 60 mg.
2012-07-06	Eli Lilly and Company	Regulatory Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta® (duloxetine HCl) lilly.com ↗ Based on this decision by the FDA, Lilly has gained an additional six months of U.S. market exclusivity for Cymbalta, which now will expire in December 2013.
2011-07-08	Wockhardt	Regulatory WOCKHARDT RECEIVES TENTATIVE US FDA APPROVAL FOR GENERIC VERSION OF DEPRESSION DRUG CYMBALTA® wockhardt.com ↗ Pharmaceutical and biotechnology major Wockhardt has received tentative approval from the United States Food & Drug Administration (US FDA) for marketing 20mg, 30mg and 60mg delayed release capsules of Duloxetine hydrochloride which is used in treatment of depression.
2010-11-24	Sun Pharmaceutical Industries, Inc.	Regulatory Sun Pharma announces USFDA tentative approval for generic Cymbalta® sunpharma.com ↗ Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.
2010-11-22	Impax Laboratories, LLC	Regulatory Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta(R) Delayed-Release 20, 30 and 60 mg Capsules amneal.com ↗ Impax Laboratories, Inc.(NASDAQ: IPXL ) today confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application for generic version of Cymbalta(R) delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules.
2010-11-04	Eli Lilly and Company	Regulatory FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain lilly.com ↗ Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of chronic musculoskeletal pain.
2010-08-19	Eli Lilly and Company	Regulatory Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta(R) to a Broader Pain Population lilly.com ↗ In addition, the committee voted positively regarding the overall safety profile of Cymbalta, including potential liver toxicity, with the majority agreeing that the benefit-risk profile warrants an expanded indication.
2010-02-03	Eli Lilly and Company	Results Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study lilly.com ↗ In a new study, 60 mg of Cymbalta(R) (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.(1)
2009-11-30	Eli Lilly and Company	Regulatory FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder lilly.com ↗ The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company (NYSE: LLY) announced today.
2009-09-11	Eli Lilly and Company	Results New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta® lilly.com ↗ New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks.(1)
2009-06-03	Eli Lilly and Company	Regulatory Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration lilly.com ↗ As projected, Eli Lilly and Company (NYSE: LLY) has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA).
2009-01-30	Eli Lilly and Company	Results Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study lilly.com ↗ In a new study, Cymbalta (duloxetine HCl) 60-120 mg, taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee.
2008-12-10	Eli Lilly and Company	Results Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) lilly.com ↗ Additionally, patients who were treated with duloxetine were less likely (p < .001) to experience a new episode of depression than those who received placebo (recurrence rates were 14.4 percent vs. 33.1 percent, respectively).
2008-12-10	Eli Lilly and Company	Results Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) lilly.com ↗ Additionally, patients who were treated with duloxetine were less likely (p < .001) to experience a new episode of depression than those who received placebo (recurrence rates were 14.4 percent vs. 33.1 percent, respectively).
2008-11-28	Eli Lilly and Company	Regulatory Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain lilly.com ↗ Eli Lilly and Company (NYSE: LLY) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain.
2008-08-25	Eli Lilly and Company	Results Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study lilly.com ↗ Data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour average pain score, compared with placebo.(1)
2008-08-22	Eli Lilly and Company	Regulatory Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder lilly.com ↗ Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta(R) (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD).
2008-06-27	Eli Lilly and Company	Regulatory European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder lilly.com ↗ The positive opinion is based upon the results of five clinical studies -- four double-blind placebo-controlled studies and a relapse prevention study -- involving more than 2,000 non-depressed adults with GAD.
2008-06-16	Eli Lilly and Company	Regulatory FDA Approves Cymbalta(R) for the Management of Fibromyalgia lilly.com ↗ The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company (NYSE: LLY) announced today.
2008-06-13	Eli Lilly and Company	Results Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study lilly.com ↗ New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) once daily experienced significant pain reduction.
2008-05-29	Eli Lilly and Company	Regulatory Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration lilly.com ↗ Eli Lilly and Company (NYSE: LLY) has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a new indication for Cymbalta(R) (duloxetine HCl) for the management of chronic pain, the company announced today.
2007-11-30	Eli Lilly and Company	Regulatory FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder lilly.com ↗ Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults.
2007-08-21	Eli Lilly and Company	Results New Data Suggest Cymbalta® Reduced Pain in Fibromyalgia Patients With and Without Depression lilly.com ↗ At three months, patients treated with 60mg per day or 120mg per day of duloxetine showed significantly greater reduction in pain and improvement in PGI-I scores compared with patients taking placebo.
2007-05-23	Eli Lilly and Company	Results In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, In Reducing Painful Symptoms in SSRI Non- or Partial-responders with Depression lilly.com ↗ These results demonstrate that a switch to duloxetine results in a significant decrease in the painful symptoms in patients with depression and was well tolerated regardless of the switch method used.
2007-05-21	Eli Lilly and Company	Results Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder lilly.com ↗ In the second study, patients treated with 60-120 mg once daily of Cymbalta experienced statistically significant improvements compared to those treated with a sugar pill (defined by mean change on SDS 5.78 vs. 3.11).
2007-05-03	Eli Lilly and Company	Results Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain lilly.com ↗ Results from the analysis of more than 1,000 patients were presented today at the annual meeting of the American Pain Society in Washington D.C.
2007-02-26	Eli Lilly and Company	Regulatory FDA Approves Cymbalta® for Treatment of Generalized Anxiety Disorder lilly.com ↗ With this approval, physicians and patients will be happy to know that there is another medication now available to treat this debilitating condition.
2006-05-22	Eli Lilly and Company	Results New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients lilly.com ↗
2006-05-09	Eli Lilly and Company	Regulatory Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder lilly.com ↗ Eli Lilly and Company (NYSE: LLY) today announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the treatment of generalized anxiety disorder.
2006-03-24	Eli Lilly and Company	Results Study Suggests Cymbalta(R) Significantly Reduces Core Anxiety Symptoms of Generalized Anxiety Disorder lilly.com ↗ Patients taking both 60mg/day and 120mg/day had significantly greater response and remission rates compared to patients taking sugar pill.
2006-02-14	Eli Lilly and Company	Results Study Finds Cymbalta(R) Was As Safe And Well-Tolerated As Routine Drug Treatments For Diabetic Nerve Pain lilly.com ↗ A long-term study of more than 200 patients found that Cymbalta (duloxetine HCl) is as safe and well- tolerated as current routine care that uses one or more medications for the management of pain caused by diabetic nerve damage.
2005-12-13	Eli Lilly and Company	Results New Study Suggests Cymbalta(R) Reduced Depression Symptoms At Least As Fast As a Leading Competitor lilly.com ↗ Cymbalta(R) (duloxetine hydrochloride) reduced symptoms of depression at least as fast as Lexapro(R) (escitalopram) by the end of two weeks, according to results from the first head-to-head study comparing the two antidepressants.
2005-06-11	Eli Lilly and Company	Results New Data Show Cymbalta Improved Physical, Social and Emotional Functioning and Overall Health of Patients With Painful Diabetic Neuropathy lilly.com ↗ That means Cymbalta patients reported significantly less interference from pain on key measures of physical functioning, including their ability to walk, work and sleep.
2005-05-24	Eli Lilly and Company	Results New Analysis Shows Duloxetine Reduced Anxiety Symptoms in Elderly Patients with Depression lilly.com ↗ Duloxetine significantly reduced anxiety symptoms in elderly patients with depression, compared with those treated with a sugar pill, according to new research presented today at the annual meeting of the American Psychiatric Association.
2005-05-24	Eli Lilly and Company	Results New Analysis Shows Cymbalta Reduced Anxiety Symptoms in Elderly Patients with Depression lilly.com ↗ Cymbalta(TM) (duloxetine HCL) significantly reduced anxiety symptoms in elderly patients with depression, compared with those treated with a sugar pill, according to new research presented today at the annual meeting of the American Psychiatric Association.
2005-03-07	Eli Lilly and Company	Results New Study Data Show Improved Cognitive Function in Elderly Patients Treated with Cymbalta for Depression lilly.com ↗ Elderly patients with depression treated with Cymbalta(R) (duloxetine hydrochloride, pronounced sim- BAWL'-tuh), 60 mg once daily, had twice as much improvement in verbal learning and recalling information than those given a sugar pill, according to new research presented Saturday at the annual meeting of the American Association for Geriatric Psychiatry.
2005-02-18	Eli Lilly and Company	Regulatory EU Scientific Committee Recommends Approval of Cymbalta(R) For the Treatment of Diabetic Peripheral Neuropathic Pain lilly.com ↗ The medical advisory board of the European Medicines Agency (EMEA), which regulates pharmaceuticals in Europe, has recommended the approval of duloxetine hydrochloride (sold in the United States as Cymbalta) as safe and effective for the management of diabetic peripheral neuropathic pain (DPNP) in adults, Eli Lilly and Company announced today.
2005-01-28	Eli Lilly and Company	Regulatory Lilly and Boehringer Ingelheim Jointly Announce the Recision of U.S. FDA Application for Duloxetine for Treatment of Stress Urinary Incontinence lilly.com ↗
2005-01-05	Eli Lilly and Company	Regulatory New Treatment for Depression Approved in Europe lilly.com ↗ Eli Lilly and Company and Boehringer Ingelheim announced today that Cymbalta®/Xeristar® (duloxetine hydrochloride)(+) has been granted marketing authorization by the European Commission for the treatment of major depressive episodes.
2004-10-18	Eli Lilly and Company	Results Cymbalta Provided Sustained Pain Relief for Women with Fibromyalgia lilly.com ↗ In the study, Cymbalta's effect on pain was independent of any effect on mood, and there was no significant difference in response rates between patients in the study with and without major depression.
2004-09-24	Eli Lilly and Company	Results New Study Shows Women with Severe Stress Urinary Incontinence May Reconsider Surgery After Experiencing the Benefits of Yentreve lilly.com ↗ All women enrolled in the study were awaiting continence surgery however, after eight weeks on Yentreve®, 20 percent of these patients reconsidered their willingness to undergo surgery.
2004-09-17	Eli Lilly and Company	Regulatory EU Scientific Committee Recommends Approval of Cymbalta lilly.com ↗ September 17, 2004 Eli Lilly and Company and Boehringer Ingelheim today announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.
2004-09-07	Eli Lilly and Company	Regulatory FDA Approves Antidepressant Cymbalta for Treatment of Pain Caused by Diabetic Peripheral Neuropathy, Which Affects Up to 5 Million Americans lilly.com ↗ The U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta® (duloxetine HCl; pronounced SIM-BALL-TA), judging it safe and effective for the management of diabetic peripheral neuropathic pain, a symptom of nerve damage that affects up to 5 million Americans, Eli Lilly and Company (NYSE: LLY) announced today.
2004-08-13	Eli Lilly and Company	Regulatory Yentreve Receives Approval Across the European Union for the Treatment of Stress Urinary Incontinence in Women lilly.com ↗ August 13, 2004 Eli Lilly and Company and Boehringer Ingelheim announced today that Yentreve™* (duloxetine hydrochloride) has been granted marketing authorization across the European Union (EU) for the treatment of moderate to severe stress urinary incontinence (SUI) in women.
2004-08-04	Eli Lilly and Company	Regulatory FDA Approves Lilly's Cymbalta for the Treatment of Depression lilly.com ↗ The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl; pronounced SIM-BALL-TA), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company announced today.
2004-07-29	Eli Lilly and Company	Results Duloxetine Clinical Study Results Show Improvement in Stress Urinary Incontinence in Women lilly.com ↗ A study presented today shows that women who transitioned from placebo to duloxetine in an open-label study reported similar improvement to that of women who took duloxetine during the preceding 12 weeks in a double-blind study.
2004-06-29	Eli Lilly and Company	Results Multiple Clinical Trial Analysis Shows Duloxetine Reduces Stress Urinary Incontinence Episodes and Improves Quality of Life for Women lilly.com ↗ Results from a worldwide, four-study meta-analysis, comparing the efficacy of duloxetine and placebo in more than 1,900 women, demonstrated a statistically significant improvement after 12 weeks, compared to placebo (p<0.001).
2004-06-24	Eli Lilly and Company	Regulatory FDA Extends Action Data for Cymbalta for Continued Analysis of Already-Submitted Data lilly.com ↗ The U.S. Food and Drug Administration has extended the action date for completion of its review of the investigational antidepressant Cymbalta® (duloxetine hydrochloride), Eli Lilly and Company (NYSE: LLY) announced today.
2001-11-19	Eli Lilly and Company	Results Eli Lilly and Company's Duloxetine Shown to Significantly Reduce Symptoms of Depression, Including Physical Symptoms lilly.com ↗ Data on duloxetine, an investigational balanced serotonin and norepinephrine reuptake inhibitor, suggest superiority over placebo and paroxetine in reducing depressive symptoms.

All press releases naming this drug 59 releases

Date	Issuer	Release
2021-02-15	Upsher-Smith Laboratories	Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths upsher-smith.com ↗
2020-07-27	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	VOLUNTARY ANNOUNCEMENT - "DULOXETINE HYDROCHLORIDE ENTERIC CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗
2019-10-16	Sun Pharmaceutical Industries, Inc.	Sun Pharma Launches Drizalma Sprinkle in the US sunpharma.com ↗
2015-09-03	Lupin Limited	Lupin launches first ever Duloxetine 40mg Delayed-Release Capsules in the US lupin.com ↗
2013-12-12	Sun Pharmaceutical Industries, Inc.	Sun Pharma announces US FDA approval for generic Cymbalta® sunpharma.com ↗
2012-07-06	Eli Lilly and Company	Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta® (duloxetine HCl) lilly.com ↗
2011-07-08	Wockhardt	WOCKHARDT RECEIVES TENTATIVE US FDA APPROVAL FOR GENERIC VERSION OF DEPRESSION DRUG CYMBALTA® wockhardt.com ↗
2011-04-27	Eli Lilly and Company	U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta lilly.com ↗
2010-11-24	Sun Pharmaceutical Industries, Inc.	Sun Pharma announces USFDA tentative approval for generic Cymbalta® sunpharma.com ↗
2010-11-22	Impax Laboratories, LLC	Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta(R) Delayed-Release 20, 30 and 60 mg Capsules amneal.com ↗
2010-11-04	Eli Lilly and Company	FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain lilly.com ↗
2010-08-19	Eli Lilly and Company	Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta(R) to a Broader Pain Population lilly.com ↗
2010-02-03	Eli Lilly and Company	Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study lilly.com ↗
2009-11-30	Eli Lilly and Company	FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder lilly.com ↗
2009-09-11	Eli Lilly and Company	New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta® lilly.com ↗
2009-06-03	Eli Lilly and Company	Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration lilly.com ↗
2009-01-30	Eli Lilly and Company	Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study lilly.com ↗
2008-12-10	Eli Lilly and Company	Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) lilly.com ↗
2008-12-10	Eli Lilly and Company	Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) lilly.com ↗
2008-11-28	Eli Lilly and Company	Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain lilly.com ↗
2008-11-18	Impax Laboratories, LLC	Impax Sued Based on Anda for Generic Cymbalta® amneal.com ↗
2008-08-25	Eli Lilly and Company	Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study lilly.com ↗
2008-08-22	Eli Lilly and Company	Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder lilly.com ↗
2008-06-27	Eli Lilly and Company	European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder lilly.com ↗
2008-06-16	Eli Lilly and Company	FDA Approves Cymbalta(R) for the Management of Fibromyalgia lilly.com ↗
2008-06-13	Eli Lilly and Company	Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study lilly.com ↗
2008-05-29	Eli Lilly and Company	Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration lilly.com ↗
2007-11-30	Eli Lilly and Company	FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder lilly.com ↗
2007-08-21	Eli Lilly and Company	New Data Suggest Cymbalta® Reduced Pain in Fibromyalgia Patients With and Without Depression lilly.com ↗
2007-05-23	Eli Lilly and Company	In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, In Reducing Painful Symptoms in SSRI Non- or Partial-responders with Depression lilly.com ↗
2007-05-21	Eli Lilly and Company	Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder lilly.com ↗
2007-05-03	Eli Lilly and Company	Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain lilly.com ↗
2007-02-26	Eli Lilly and Company	FDA Approves Cymbalta® for Treatment of Generalized Anxiety Disorder lilly.com ↗
2006-05-22	Eli Lilly and Company	New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients lilly.com ↗
2006-05-09	Eli Lilly and Company	Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder lilly.com ↗
2006-03-24	Eli Lilly and Company	Study Suggests Cymbalta(R) Significantly Reduces Core Anxiety Symptoms of Generalized Anxiety Disorder lilly.com ↗
2006-02-15	Eli Lilly and Company	Eli Lilly and Company and Boehringer Ingelheim Announce Changes to Their Contractual Agreements for Yentreve® AriClaim® lilly.com ↗
2006-02-14	Eli Lilly and Company	Study Finds Cymbalta(R) Was As Safe And Well-Tolerated As Routine Drug Treatments For Diabetic Nerve Pain lilly.com ↗
2005-12-13	Eli Lilly and Company	New Study Suggests Cymbalta(R) Reduced Depression Symptoms At Least As Fast As a Leading Competitor lilly.com ↗
2005-12-09	Eli Lilly and Company	Lilly Plans to Submit Cymbalta(R) (duloxetine hydrochloride) New Drug Application for Generalized Anxiety Disorder lilly.com ↗
2005-06-11	Eli Lilly and Company	New Data Show Cymbalta Improved Physical, Social and Emotional Functioning and Overall Health of Patients With Painful Diabetic Neuropathy lilly.com ↗
2005-05-24	Eli Lilly and Company	New Analysis Shows Duloxetine Reduced Anxiety Symptoms in Elderly Patients with Depression lilly.com ↗
2005-05-24	Eli Lilly and Company	New Analysis Shows Cymbalta Reduced Anxiety Symptoms in Elderly Patients with Depression lilly.com ↗
2005-03-07	Eli Lilly and Company	New Study Data Show Improved Cognitive Function in Elderly Patients Treated with Cymbalta for Depression lilly.com ↗
2005-02-18	Eli Lilly and Company	EU Scientific Committee Recommends Approval of Cymbalta(R) For the Treatment of Diabetic Peripheral Neuropathic Pain lilly.com ↗
2005-01-28	Eli Lilly and Company	Lilly and Boehringer Ingelheim Jointly Announce the Recision of U.S. FDA Application for Duloxetine for Treatment of Stress Urinary Incontinence lilly.com ↗
2005-01-05	Eli Lilly and Company	New Treatment for Depression Approved in Europe lilly.com ↗
2004-10-18	Eli Lilly and Company	Cymbalta Provided Sustained Pain Relief for Women with Fibromyalgia lilly.com ↗
2004-09-24	Eli Lilly and Company	New Study Shows Women with Severe Stress Urinary Incontinence May Reconsider Surgery After Experiencing the Benefits of Yentreve lilly.com ↗
2004-09-17	Eli Lilly and Company	EU Scientific Committee Recommends Approval of Cymbalta lilly.com ↗
2004-09-13	Eli Lilly and Company	Yentreve lilly.com ↗
2004-09-07	Eli Lilly and Company	FDA Approves Antidepressant Cymbalta for Treatment of Pain Caused by Diabetic Peripheral Neuropathy, Which Affects Up to 5 Million Americans lilly.com ↗
2004-08-24	Eli Lilly and Company	Lilly Launches New Antidepressant Cymbalta lilly.com ↗
2004-08-13	Eli Lilly and Company	Yentreve Receives Approval Across the European Union for the Treatment of Stress Urinary Incontinence in Women lilly.com ↗
2004-08-04	Eli Lilly and Company	FDA Approves Lilly's Cymbalta for the Treatment of Depression lilly.com ↗
2004-07-29	Eli Lilly and Company	Duloxetine Clinical Study Results Show Improvement in Stress Urinary Incontinence in Women lilly.com ↗
2004-06-29	Eli Lilly and Company	Multiple Clinical Trial Analysis Shows Duloxetine Reduces Stress Urinary Incontinence Episodes and Improves Quality of Life for Women lilly.com ↗
2004-06-24	Eli Lilly and Company	FDA Extends Action Data for Cymbalta for Continued Analysis of Already-Submitted Data lilly.com ↗
2001-11-19	Eli Lilly and Company	Eli Lilly and Company's Duloxetine Shown to Significantly Reduce Symptoms of Depression, Including Physical Symptoms lilly.com ↗

Evidence & citations 33 cited values

Every value below carries the sentence it was read from. 392 sources stand behind the page.

Field	Value	Cited text
Known as	duloxetine	“we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These...” NCT02458690 ↗ 379 “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗ “Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346 ↗ “Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week...” NCT00854100 ↗ “SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine...” NCT01436175 ↗ “This study will determine the influence of methylphenidate (e.g., Ritalin®) and duloxetine (Cymbalta®), alone and in combination, on the cocaine use as measured by self-report...” NCT02700711 ↗ “If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will...” NCT04478526 ↗ “Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.” NCT00742573 ↗ “quantifying the range of concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, duloxetine and venlafaxine in mother plasma and breast milk” NCT01796132 ↗ “The drugs included in the treatment plan are morphine (60 mg/day), pregabalin (150 mg/day) and duloxetine (60 mg/day), available free of charge to the participating patients.” NCT05558397 ↗ Show 369 more sources
Known as	Ariclaim	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Cymbalta	“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ 23 “Experimental: Duloxetine group 1. Phase I (preemptive): 1day before operation (30mg for 1 day) 2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus...” NCT02600247 ↗ “Duloxetine(Cymbalta) for Fibromyalgia: An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic...” NCT01127490 ↗ “The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients...” NCT00185575 ↗ “Duloxetine ("Cymbalta") is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy.” NCT03271151 ↗ “Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.” NCT03794154 ↗ “Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.” NCT03729284 ↗ “35 patients will receive duloxetine (Cymbalta; Eli Lilly \& Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.” NCT03037073 ↗ “Duloxetine (Cymbalta) is one of the newer antidepressants approved for the treatment of Major Depressive Disorder (MDD).” NCT00517985 ↗ “pain relievers such as acetaminophen and antidepressants such as Duloxetine (Cymbalta) and milnacipran” NCT07533487 ↗ “impact of duloxetine ("Cymbalta"), a serotonin and norepinephrine reuptake inhibitor” NCT02005601 ↗ Show 13 more sources
Known as	Cymbalta (duloxetine)	“Cymbalta (duloxetine)” NCT00889369 ↗
Known as	Cymbatex	“one capsule of Duloxetine 30 mg (Cymbatex 30 mg, EVA Pharma)” NCT07421427 ↗
Known as	DLX	“Duloxetine (DLX)” NCT00945945 ↗
Known as	Drizalma sprinkle	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Duciltia	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	DUL	“45 patients will be assigned into each group, by order of their recruitment. Third of the patients in each group will be randomized to Duloxetine (DUL), third to Pregabalin...” NCT02672202 ↗
Known as	Duloxetina	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Duloxetine (as hydrochloride)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Duloxetine boehringer ingelheim	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Duloxetine HCl	“In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.” NCT03792828 ↗ 1 “Totally, 144 received 60 mg/day of duloxetine HCL and 144 received placebo for 16 weeks.” PMID 22743149 ↗ Jun 2012
Known as	Duloxetine Hydrochloride	“To determine the dosage of duloxetine hydrochloride (duloxetine) (30 mg or 60 mg daily) that appears most promising in preventing oxaliplatin-induced peripheral neuropathy (OIPN).” NCT04137107 ↗ 19 “Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.” NCT03794154 ↗ “Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.” NCT03729284 ↗ “Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.” NCT04364997 ↗ “Duloxetine Hydrochloride (LY248686) Protocol F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain” NCT00036335 ↗ “Generic Duloxetine Hydrochloride (Germed) will be purchased and sent for fractioning and placebo preparation.” NCT07203339 ↗ “Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.” NCT05508516 ↗ “Cymbalta® (duloxetine hydrochloride 60 mg, delayed-release capsule)” NCT06715462 ↗ “Drug: Duloxetine hydrochloride” NCT00583193 ↗ “Drug: duloxetine hydrochloride” NCT00385671 ↗ “Drug: duloxetine hydrochloride” NCT00673452 ↗ Show 9 more sources
Known as	Duloxetine Hydrochloride Enteric Capsules	“Duloxetine Hydrochloride Enteric Capsules 60mg/day is to be given orally, once daily, for 8 weeks.” NCT07253207 ↗
Known as	Duloxetine lilly	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Duloxetine mylan	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Duloxetine zentiva	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Duloxetine, Cymbalta	“Duloxetine, Cymbalta” NCT01916824 ↗
Known as	Dulsevia	“Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.” NCT04246619 ↗
Known as	Duroceptol	“In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.” NCT03792828 ↗
Known as	LY-248686 HCL	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	LY248686	“Duloxetine Hydrochloride (LY248686) Protocol F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain” NCT00036335 ↗
Known as	Nodetrip (previously xeristar)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	NSC-759112	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Xeristar	ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗
Known as	Yentreve	“duloxetine_Cymbalta, Yentreve” NCT00817011 ↗
Action	Inhibit	“The purpose of this non-inferiority study was to compare the speed of onset of antidepressant efficacy for duloxetine (a dual serotonin and norepinephrine reuptake inhibitor)...” PMID 17288694 ↗ Feb 2007 2 “Norepinephrine transporter inhibitor” CHEMBL1175 ↗ “Serotonin transporter inhibitor” CHEMBL1175 ↗
Modality	Small molecule	“Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI)” NCT00438971 ↗
Route	Oral	“duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks” NCT00105989 ↗
Target	CYP2D6	“Duloxetine is known to inhibit CYP2D6.” NCT01443520 ↗
Target	SLC6A2	“Norepinephrine transporter inhibitor” CHEMBL1175 ↗
Target	SLC6A4	“Serotonin transporter inhibitor” CHEMBL1175 ↗